Cambridge Cognition Ltd

Cambridge Cognition (AIM: COG) is a UK-based cognitive technology company that develops and licenses the CANTAB neuropsychological assessment platform, validated in over 3,000 publications and widely adopted in psychedelic clinical trials—including psilocybin and MDMA studies—to objectively measure cognitive outcomes at baseline, during, and after treatment. CANTAB’s digital cognitive assessments have become a de facto standard endpoint tool in psychiatric drug development, supporting the field’s progression through Phase 2 and Phase 3 psychedelic trials.